EyePoint Pharmaceuticals, Inc. (EYPT) vs Lexeo Therapeutics, Inc. Common Stock (LXEO)

A side-by-side comparison of EyePoint Pharmaceuticals, Inc. and Lexeo Therapeutics, Inc. Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
EyePoint Pharmaceuticals, Inc. logo
EYPT
EyePoint Pharmaceuticals, Inc.
$260M
$3.10HealthcareDelayed quote: Oct 6, 2026, 10:25 AM EDT
Lexeo Therapeutics, Inc. Common Stock logo
LXEO
Lexeo Therapeutics, Inc. Common Stock
$250M
$3.19HealthcareDelayed quote: Oct 6, 2026, 10:25 AM EDT

Total return — EYPT vs LXEO

growth of $100 · dividends reinvested · last 3y
EYPT -47.7% (-19.4%/yr)LXEO -66.1% (-30.3%/yr)EYPT compounded faster over this window
0100200300400500Start $100202420252026$52$34
EYPT LXEO

EYPT vs LXEO: by the numbers

  • •EYPT is the larger company ($260M vs $250M market cap).
  • •Both run net losses; LXEO's is the smaller (0.00% vs -10994.73% net margin).

Metrics side by side

Valuation

MetricEYPTLXEO
P/S ratio93.19N/A
P/B ratio1.561.06

Profitability

MetricEYPTLXEO
Gross margin93.41%0.00%
Operating margin-775.98%0.00%
Net margin-10994.73%0.00%
ROE-184.27%-37.12%
ROIC-170.19%-39.76%

Growth (annualized)

MetricEYPTLXEO
Revenue CAGR (5Y)-41.05%N/A
Total return CAGR (5Y)-21.68%N/A

Go deeper

Full EYPT analysisFull LXEO analysisInteractive comparison tool

Dig into the metrics

EyePoint Pharmaceuticals ROELexeo Therapeutics, Inc. Common Stock ROEEyePoint Pharmaceuticals operating marginLexeo Therapeutics, Inc. Common Stock operating marginEyePoint Pharmaceuticals revenue growthLexeo Therapeutics, Inc. Common Stock revenue growthEyePoint Pharmaceuticals free cash flowLexeo Therapeutics, Inc. Common Stock free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.